New cancer drug combo tested for safety in advanced tumors
NCT ID NCT05147350
Summary
This early-stage study tested a new oral drug, RP-6306, given alongside a standard chemotherapy regimen (FOLFIRI) in adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find the safest dose, understand side effects, and see if the combination showed any early signs of fighting the cancer. The study was terminated after enrolling 38 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
# 2001, Princess Margaret Cancer Centre
Toronto, Ontario, ON M5G 2M9, Canada
-
# 3003, Sarah Cannon Research Institute
London, W1G 6AD, United Kingdom
-
# 5002, South Texas Accelerated Research Therapeutics
Madrid, Spain
-
# 5003, Hospital Universitario HM Sanchinarro
Madrid, Spain
-
#1001, The University of Texas M.D. Anderson Cancer Center
Houston, Texas, 77030, United States
-
#1008, Columbia University
New York, New York, 10032, United States
-
#1013, The University of Utah, Huntsman Cancer Center
Salt Lake City, Utah, 84112, United States
-
#1019, UCLA, Westwood Cancer Center
Los Angeles, California, 90095, United States
-
#1022, Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.